ENvue Medical (FEED) investor Glibert now holds 6.5% after share dilution

Rhea-AI Filing Summary

Christian Michael Glibert reports an updated beneficial ownership position in ENvue Medical, Inc. common stock. He continues to hold 240,000 shares, which now represent 6.5% of the company’s outstanding common stock.

The change in percentage results from ENvue Medical’s total shares outstanding increasing from 1,088,192 to 3,700,908, as disclosed in the company’s Annual Report on Form 10‑K filed on April 15, 2026. Glibert has not acquired or disposed of any shares since his initial Schedule 13D filed on February 11, 2026 and states he holds the position for investment purposes, while reserving the option to buy or sell shares in the future depending on market conditions.

Insights

Equity ownership and governance analyst

Glibert’s ENvue stake is unchanged in shares but diluted in percentage terms.

The disclosure shows Christian Michael Glibert still holds 240,000 ENvue Medical shares, but his stake has fallen from about 22.1% to 6.5%. The drop stems from ENvue’s share count rising from 1,088,192 to 3,700,908, not from his trading.

Because Glibert has not bought or sold since the initial Schedule 13D, this is a structural dilution effect rather than a change in conviction. His continued investment intent and sole voting and dispositive power over the shares suggest stable ownership, while future activity will depend on market conditions and other factors mentioned.

Key Figures

Beneficially owned shares: 240,000 shares Current ownership percentage: 6.5% Prior ownership percentage: 22.1% +4 more

7 metrics

Beneficially owned shares 240,000 shares Reported ENvue Medical common stock beneficially owned

Current ownership percentage 6.5% Percent of ENvue Medical common stock represented by 240,000 shares

Prior ownership percentage 22.1% Approximate percentage before share count increased

Shares outstanding before 1,088,192 shares ENvue Medical total shares outstanding before increase

Shares outstanding after 3,700,908 shares ENvue Medical total shares outstanding as referenced in Form 10-K

Event date 01/14/2026 Date of event requiring updated beneficial ownership disclosure

Initial 13D filing date February 11, 2026 Date initial Schedule 13D was filed

Key Terms

beneficial ownership, sole power to vote, sole power to dispose, Schedule 13D, +2 more

6 terms

beneficial ownership financial

"to report a material change in the Reporting Person's percentage of beneficial ownership of the Issuer's Common Stock."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole power to vote financial

"Sole power to vote: 240,000 Shared power to vote: 0"

sole power to dispose financial

"Sole power to dispose: 240,000 Shared power to dispose: 0"

Schedule 13D regulatory

"Since the filing of the initial on February 11, 2026, the Issuer's total shares outstanding increased"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

dilution financial

"This increase in outstanding shares resulted in the dilution of the Reporting Person's beneficial ownership from approximately 22.1 percent to approximately 6.5 percent."

Dilution occurs when a company issues additional shares, increasing the total number of shares outstanding. This can reduce the ownership percentage and voting power of existing shareholders, similar to slicing a pie into more pieces—each piece becomes smaller. For investors, dilution can mean a reduced stake in the company and potentially lower earnings per share, affecting the value of their investment.

contracts, arrangements, understandings or relationships regulatory

"Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

ENvue Medical, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

63008J884

(CUSIP Number)

Christian Glibert
4001 Green Heron Spring Drive,
Carpinteria, CA, 93013
740-507-7228

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

01/14/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 63008J884

1

Name of reporting person

Glibert Christian Michael

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power
8	Shared Voting Power
9	Sole Dispositive Power
10	Shared Dispositive Power

11

Aggregate amount beneficially owned by each reporting person

240,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

6.5 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: ENvue Medical, Inc.
(c)	Address of Issuer's Principal Executive Offices: 969 PRUITT AVE,, 969 PRUITT AVE,, TYLER, TEXAS , 77569.
Item 4.	Purpose of Transaction
	This Amendment No. 1 to Schedule 13D is being filed to report a material change in the Reporting Person's percentage of beneficial ownership of the Issuer's Common Stock. Since the filing of the initial Schedule 13D on February 11, 2026, the Issuer's total shares outstanding increased from 1,088,192 to 3,700,908, as reported in the Issuer's Annual Report on Form 10-K filed on April 15, 2026. This increase in outstanding shares resulted in the dilution of the Reporting Person's beneficial ownership from approximately 22.1 percent to approximately 6.5 percent. The Reporting Person has not acquired or disposed of any shares of Common Stock since the initial filing. The Reporting Person continues to hold the shares for investment purposes and may, from time to time, purchase additional shares or dispose of existing shares in the open market or in private transactions, depending on market conditions and other factors.
Item 5.	Interest in Securities of the Issuer
(a)	240,000 shares which is 6.5% of shares
(b)	Sole power to vote: 240,000 Shared power to vote: 0 Sole power to dispose: 240,000 Shared power to dispose: 0
(c)	none
(d)	not applicable
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information set forth in Item 6 of the initial Schedule 13D is incorporated herein by reference. There have been no material changes to the contracts or arrangements previously reported.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Glibert Christian Michael

Signature:	/s/ Christian Michael Glibert
Name/Title:	Christian Michael Glibert / Individual
Date:	04/17/2026

FAQ

How many ENvue Medical (FEED) shares does Christian Michael Glibert beneficially own?

Christian Michael Glibert beneficially owns 240,000 shares of ENvue Medical common stock. These shares represent his entire reported position, over which he has sole voting and dispositive power, as described in the updated beneficial ownership disclosure.

What percentage of ENvue Medical (FEED) does Glibert’s 240,000 shares represent?

Glibert’s 240,000 shares represent 6.5% of ENvue Medical’s outstanding common stock. This percentage reflects the company’s expanded share count of 3,700,908 shares, as referenced in its most recent Annual Report on Form 10-K.

Why did Christian Michael Glibert’s ENvue Medical (FEED) ownership percentage decline?

His ownership percentage declined because ENvue Medical’s outstanding shares increased from 1,088,192 to 3,700,908. Although Glibert kept his 240,000-share position unchanged, the larger share base reduced his stake from about 22.1% to about 6.5%.

Has Christian Michael Glibert bought or sold ENvue Medical (FEED) shares since his initial Schedule 13D?

No. The disclosure states Glibert has not acquired or disposed of any shares of ENvue Medical common stock since the initial Schedule 13D filing. The change in his ownership percentage stems solely from the company’s increased outstanding share count.

What are Glibert’s voting and dispositive powers over his ENvue Medical (FEED) shares?

Glibert reports sole power to vote and dispose of 240,000 shares, with zero shared voting or dispositive power. This means he alone controls how these shares are voted and whether or when they are sold or otherwise transferred.

What is Glibert’s stated purpose for holding ENvue Medical (FEED) shares?

Glibert states he holds his ENvue Medical shares for investment purposes. He may buy additional shares or sell existing ones in open-market or private transactions over time, depending on market conditions and other factors he considers important.